Zai Lab (STU:1ZLB) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:1ZLB Zai Lab Ltd STU:1ZLB
68 GF Score
Price €1.68
GF Value €2.65
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Zai Lab FFO?

FFO (Funds from operations) only applies to REITs.

STU:1ZLB
68GF Score
Zai Lab Ltd STU:1ZLB
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Zai Lab (STU:1ZLB) Overvalued in 2026?

Based on GuruFocus' analysis, Zai Lab stock appears to be undervalued. The current stock price of €1.68 is trading 36.6% below its estimated GF Value™ of €2.65. GuruFocus considers Zai Lab to be Possible Value Trap.

Key valuation signals for STU:1ZLB:

  • FFO:
  • GF Value™: €2.65 vs. price of €1.68 (36.6% below fair value)
  • GF Score™: 68/100 with 7 warning signs

No single metric tells the full story. See the STU:1ZLB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Zai Lab Business Description

Other Exchanges ZLAB:USA09688:Hong Kong
Address 899 Halei Road, Building B, Pudong, Shanghai, CHN, 201203
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.
68GF Score

Get the complete analysis for STU:1ZLB

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.68
Price
€2.65
GF Value